BIO RAD LABORATORIES INC. – LIQUICHEK TUMOR REGEANTS
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), Clinical Center, intends to award a sole source firm-fixed-price contract to Bio-Rad Laboratories for the procurement of Liquichek Tumor Regeants. This presolicitation notice is for informational purposes only and does not constitute a request for quotations. Interested parties may submit capability statements by May 24, 2026, at 8:00 AM EST.
Scope of Requirement
The requirement is for testing controls for cardiac, cancer, and infectious disease markers, specifically Liquichek Tumor Regeants. These reagents are crucial for providing consistent, high-quality results for clinical center patients within the Department of Laboratory Medicine (DLM) Immunoassay laboratory. The DLM Immunoassay laboratory supports 35 protocols requiring highly accurate and rapid results, with some research protocols extending over several years, necessitating consistent laboratory values using the same testing methodologies.
Contract & Timeline
- Type: Sole Source Firm-Fixed-Price Contract (Presolicitation)
- Set-Aside: None (Sole Source)
- Response Due: May 24, 2026, 8:00 AM EST
- Published: May 14, 2026
- Place of Performance: National Institutes of Health, Clinical Center, Bethesda, MD 20892
Rationale & Authority
This acquisition is being conducted as a sole source because Bio-Rad Laboratories is the sole manufacturer of Liquichek Tumor Regeants. Substitution is not permissible without revalidation and regulatory approval, which could delay patient treatment and pose risks to patient care. The acquisition is authorized under FAR 13.106-1(b)(1), allowing solicitation from a single source when only one is reasonably available. Acquisitions under FAR Part 13 are exempt from FAR Part 6 competition requirements.
Submission Instructions
While this is not a request for quotations, interested parties may submit a capability statement demonstrating their ability to meet the Government's requirement. Responses must include:
- Company name and address
- Technical capability
- Proof of OEM authorization
- Relevant past performance
Responses, referencing POTS: 26-005107, must be submitted electronically to Gregory Noland at gregory.noland@nih.gov. The Government will evaluate statements, but the determination not to compete remains at its discretion.